MYL10: A Potential Cancer Therapeutic and Biomarker (G93408)
MYL10: A Potential Cancer Therapeutic and Biomarker
Myl10 (Promyelocybin Derivative Ligand 10) is a protein that is expressed in various cell types in the human body. It is a member of the Pheromone Family and has been identified as a potential drug target (or biomarker) in the field of cancer.
MYL10 is a cytoplasmic protein that is expressed in various cell types, including epithelial, endothelial, and neural cells. It is characterized by the presence of a long N-terminal cytoplasmic tail, a characteristic feature of proteins that interact with cell surface receptors.
One of the unique features of MYL10 is its ability to induce cell proliferation in a variety of cell types. In fact, studies have shown that MYL10 can promote the growth of cancer cells in a number of different models, including cell lines and animal models.
This properties make MYL10 an intriguing candidate for drug development as a cancer therapeutic. IfMYL10 can be effectively targeted and inhibited in cancer cells, it could potentially be used to treat a wide range of cancer types.
Another feature of MYL10 is its ability to interact with specific proteins, including the transcription factor NF-kappa-B. This interaction between MYL10 and NF-kappa-B has been shown to play a role in the regulation of cell proliferation and survival.
In addition to its potential role as a drug target, MYL10 also has potential as a biomarker for cancer. The ability ofMYL10 to induce cell proliferation in a variety of cell types makes it a potentially useful marker for tracking the effectiveness of different cancer treatments.
MYL10 has also been shown to be expressed in a variety of different cancer types, including breast, lung, and ovarian cancer. This makes it a potentially useful biomarker for these types of cancer as well.
In conclusion, MYL10 is a protein that has intriguing properties as a potential drug target and biomarker for cancer. Further research is needed to fully understand its role in the regulation of cell proliferation and survival, and to explore its potential as a therapeutic agent.
Protein Name: Myosin Light Chain 10
More Common Targets
MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5 | MYL6 | MYL6B | MYL7 | MYL9 | MYLIP | MYLK | MYLK-AS1 | MYLK-AS2 | MYLK2 | MYLK3 | MYLK4 | MYLKP1 | MYMK | MYMX | MYNN | MYO10 | MYO15A | MYO15B | MYO16 | MYO16-AS1 | MYO16-AS2 | MYO18A | MYO18B | MYO19 | MYO1A | MYO1B | MYO1C | MYO1D | MYO1E | MYO1F | MYO1G | MYO1H | MYO3A | MYO3B | MYO3B-AS1 | MYO5A | MYO5B | MYO5C | MYO6 | MYO7A | MYO7B | MYO9A | MYO9B | MYOC | MYOCD | MYOD1 | MYOF | MYOG | MYOM1 | MYOM2 | MYOM3 | MYORG | Myosin | Myosin class II | Myosin light-chain phosphatase | MYOSLID | MYOSLID-AS1 | MYOT | MYOZ1 | MYOZ2 | MYOZ3 | MYPN | MYPOP | MYRF | MYRF-AS1 | MYRFL | MYRIP | MYSM1 | MYT1 | MYT1L | MYT1L-AS1 | MYZAP | MZB1 | MZF1 | MZF1-AS1 | MZT1 | MZT2A | MZT2B | N-acetylglucosamine-1-phosphotransferase | N-CoR deacetylase complex | N-Terminal Acetyltransferase A (NatA) Complex | N-Terminal Acetyltransferase C (NatC) Complex | N-Type Calcium Channel | N4BP1 | N4BP2 | N4BP2L1 | N4BP2L2 | N4BP2L2-IT2 | N4BP3 | N6AMT1 | NAA10 | NAA11